Predictmedix Inc

Predictmedix — Investor Presentation (January 2023)

29 slides from Predictmedix's investor presentation, January 2023

  1. Slide 1: Predictmedix

    PREDICTMEDIX.COM CSE : PMED OTCQB : PMEDF

  2. Slide 2: Disclaimer and forward-looking statements

    Predictmedix Inc. (the ”Company”) is a reporting issuer under the Securities Exchange Act of 1934 (the “34 Act”). Further information about the Company is available at the SEC’s EDGAR website at: https://www.sec.gov/edgar/browse/?CIK=1878079&owner=exclude This presentation is qualified by the Compan

  3. Slide 3: Predictmedix company overview

    Predictmedix is an emerging provider of rapid health screening, medical devices, and remote patient care solutions globally. The Company’s Safe Entry Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological Predictmedix data patterns and i

  4. Slide 4: The Current Landscape

    The Current Landscape Triage Fatigue and Infectious Mental Solution & Impairment Diseases Illnesses Virtual Care 4 Fit for Duty Screening Solutions CSE : PMED OTCQB : PMEDF

  5. Slide 5: Problem and Solution

    PROBLEM SOLUTION • Workplace impairment from Cannabis • Predictmedix’s Fit for Duty screening offers and Alcohol is a costly burden to companies a non-invasive, autonomous, companies around the world. non-biased, and cost-efficient way to ensure workers are Fit for Duty. • More than 43% of workers a

  6. Slide 6: Safe Entry Station

    SAFE a 6 eave ENTRY , “i STATION iil TIMI OST 2 INFLUENTIAL PERSONALITIES Etsscore S| CSE: PMED OTCQB

  7. Slide 7: Validated technology through peer-reviewed publications

    Validated technology through peer- reviewed publications Unfit workers are a liability to every business. Unfit workers can be classified as being impaired from alcohol or cannabis, extreme fatigue, and infectious and clinical trails diseases. There is a high cost associated to the performance of un

  8. Slide 8: Impairment detection from cannabis and alcohol

    Employers, as well as law enforcement, test people for traces of cannabis, alcohol and opioids. However, they cannot determine if individuals are actually impaired. Without the ability to determine impairment, it is impossible to accurately predict safety risk, particularly for employees operating h

  9. Slide 9: Infectious disease detection including COVID-19

    Infections including COVID-19, produce unique physiological patterns that our solution will detect, assess and then make a determination as to the probability of that person being infected or not infected. Real time assessment will indicate whether follow-up testing is needed. As the virus mutates,

  10. Slide 10: Fit for Duty screening across industries

    § Infectious diseases § Impairment from Construction. Mining. Warehouses. Manufacturing. Corporate Offices. cannabis & alcohol And more. § Extreme fatigue § Mental health Many laws restrict employers to test for drugs on a regular basis. Additionally, drug testing isn’t an affordable solution, and d

  11. Slide 11: Immense growth and demand in the Workplace Safety market

    Immense growth and demand in the Workplace Safety market The global workplace safety market is projected to grow from an estimated $14.2 billion USD in 2022 to $26.7 billion USD by 2027 at a Compound Annual Growth Rate (CAGR) of 13.5 %1 Safe Entry is positioned at the forefront of workplace Health a

  12. Slide 12: Competitive Landscape

    Competitive Landscape Impairment Commercialization Company AI Non-Invasive Notes Detection Stage Cannabix Breathalyzer Pre-commercialization Hound Marijuana Breathalyzer Unknown how it determines impairment and may rely on amount of cannabinoids to Pre-commercialization apply a rating for potential

  13. Slide 13: First Diagnostic Tool: mental illness screening

    Predictmedix believes its technology may be expanded in the future to enable First Diagnostic Tool screening for certain mental illnesses. Mental illness is difficult to detect at early stages, primarily due to a lack of diagnostic tools other than standardized Predictmedix Mental Illness Diagnostic

  14. Slide 14: Clinical studies at North American Hospital

    Clinical studies at North American Clinical studies were completed at a North American Hospital where Predictmedix’s infectious diseases and impairment detection solutions Hospital were evaluated in order to fulfill a prerequisite for certification with the U.S Food and Drug Administration (FDA). In

  15. Slide 15: Successful Peer-reviewed publications

    Clinical Validation and peer-reviewed medical journals 4 Successful Peer- reviewed publications 15 CSE : PMED OTCQB : PMEDF

  16. Slide 16: Safe Entry Stations are CE Mark and ISO Certified

    Safe Entry Stations are CE Mark and ISO Certified The CE mark declares the conformity of the Safe Entry Station with EU regulations and indicates that a product has been assessed by the manufacturer and deemed to meet EU safety, health and environmental protection requirements. ISO 13485 is the medi

  17. Slide 17: Building value through AI-powered medical devices

    Building value through AI-powered Predictmedix’s R&D strategy focuses on developing AI-powered medical devices medical devices for healthcare, workplace, law enforcement, public spaces, and more. that can save lives Predictmedix’s AI algorithms are constantly improving Predictmedix is dedicated to r

  18. Slide 18: Organizations and facilities adopting or testing Safe Entry Stations

    Leading organizations and healthcare facilities are adopting or testing Safe Entry Stations MGM Healthcare Paras Defence & Space Indian Oil Corporation Hospitals Technologies Office Facilities Sparta Health Optima Living ICFF Film Festival Healthcare Clinics Seniors Residences Public Event Flow Wate

  19. Slide 19: Recurring SaaS Fee, Multi-Year Contracts

    Screening as a Service (SaaS) drives: • High-Margin Revenue • Recurring Revenue • Multi-Year Contracts Recurring SaaS Fee Multi-Year Contracts $5,000/month Our customers invest in our technology not as a reaction Screening as a Service (SaaS) to COVID, but with the long-term understanding that prici

  20. Slide 20: The biggest and best believe in our solutions

    The biggest and best believe in our solutions Tech Mahindra Predictmedix has signed Joint Paras Defence Venture agreements with Tech Mahindra, who will resell North American Resellers Predictmedix secured a reseller Predictmedix to their global client agreement with Paras Defence, an • Juiceworks Ex

  21. Slide 21: Mainstream, trade, and investor media

    Mainstream, trade, and investor media are actively pursuing Predictmedix for interviews and features. 21 CSE : PMED OTCQB : PMEDF

  22. Slide 22: Triage Screening Solution data collection at hospitals

    The current method of collecting incoming patient data in hospital settings is cumbersome, time-consuming, and a nightmare for nurses and doctors. Data collection at Predictmedix is developing an AI powered Triage Screening multiple hospitals Solution to help Health Care Workers make quicker, import

  23. Slide 23: Remote patient monitoring and Telehealth platform

    Remote patient monitoring & Telehealth platform for healthcare, LTC, and employers Long Term Care (LTC) Clinical Research Large Scale and Retirement Residences Organizations (CRO) Employees Covid-19 has revealed the devastating Traditional methods of on-site monitoring Existing human resource platfo

  24. Slide 24: U.S. patents have been filed

    Protecting our Technology in Key Global markets 6 U.S. PATENTS HAVE BEEN FILED 25 CSE : PMED OTCQB : PMEDF

  25. Slide 25: Management team

    Sheldon Kales Dr. Rahul Kushwah Rakesh Malhotra Ankur Bisht Rajiv Muradia CEO COO AI Lead VP, Technology CFO § Expertise in operations, § PhD, Banting Fellow § Artificial Intelligence § Mobile Wellbeing § CPA designation in business strategy and (one of 23 global pioneer in translational Founder US

  26. Slide 26: Management and board

    Sheldon Kales Dr. Rahul Kushwah Tomas Sipos § Expertise in operations, business § PhD, Banting Fellow § Seasoned investment banker strategy and capital markets § Developed world’s first genetic § Has held several senior positions, § Held leadership roles operating R&D test for cannabis pharmacogenet

  27. Slide 27: Advisory Board

    Advisory MSc, PhD MBBS, MS, DNB Board § Neurosurgeon with over 34 years’ experience in § One of India’s leading thoracic surgeons, practicing in BLK microscopic and minimal invasive neurosurgery Super Speciality Hospital, the largest stand-alone private § Sugita Fellow from Nagoya University, Japan

  28. Slide 28: Safe Entry positioned at the forefront of workplace safety

    Safe Entry is being positioned at the forefront of workplace health and safety solutions. The global workplace safety market is projected to grow from an estimated $14.2 billion USD in 2022 to $26.7 billion USD by 2027 at a Compound Annual Growth Rate (CAGR) of 13.5 %1. Predictmedix has developed no

  29. Slide 29: Corporate information and contact

    CSE : PMED OTCQB : PMEDF PREDICTMEDIX.COM CORPORATE INFORMATION 77 King Street West, Suite 3000 Toronto, ON, Canada M5K 2A1 CONTACT Rahul Kushwah COO – Predictmedix Rahul@predictmedix.com

Predictmedix — Investor Presentation (January 2023) on 6ix